NeuroMetrix announced the full commercial launch of Quell, which is now available on the Company’s product website at QuellRelief.com and at select physicians’ offices.
Quell is an easy-to-use, over-the-counter chronic pain relief device. This first-of-its-kind wearable device utilizes NeuroMetrix’s patented, non-invasive nerve stimulation technology to provide 100 percent drug-free chronic pain relief.
It is designed for people with painful diabetic neuropathy, sciatica, osteoarthritis and fibromyalgia, among other conditions.
"There are an estimated 100 million people living with chronic pain in the U.S., and many are not experiencing adequate relief with currently available treatment options or want to avoid opioid medications that may incur added risk and side effects," says Dr. Paul Christo, Pain Specialist and Host of the nationally syndicated radio show Aches and Gains.
"I am excited by the possibilities non-medication options like wearable transcutaneous electrical nerve stimulation (TENS) devices can provide people living with chronic pain, particularly because they do not carry a risk of opioid dependence and side effects, and do not require invasive surgeries."
New York native Jesse Alberio has been living with painful diabetic neuropathy for over two years. After trying a number of different medications to control the pain, he was still experiencing burning and numbness in his lower extremities.
A recent study conducted by the National Sleep Foundation found that nearly one in four people living with chronic pain reported having poor or very poor sleep quality.
Limitations of traditional transcutaneous nerve stimulation devices leave chronic pain sufferers without relief at night; Quell is the only FDA cleared device of its kind approved for use while sleeping. A built-in accelerometer detects when a person is sleeping and then automatically adjusts the level of therapy so it will not disturb their sleep.
Quell received FDA clearance in July 2014 for chronic pain relief and use during nighttime sleep without a prescription. The FDA submission for Quell was based on its predecessor, SENSUS, which has provided over 2.5 million hours of therapy to chronic pain sufferers throughout the US.